311 related articles for article (PubMed ID: 27249171)
1. The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling.
Ji YX; Zhang P; Zhang XJ; Zhao YC; Deng KQ; Jiang X; Wang PX; Huang Z; Li H
Nat Commun; 2016 Jun; 7():11267. PubMed ID: 27249171
[TBL] [Abstract][Full Text] [Related]
2. Phosphoinositide-dependent kinase-1 inhibits TRAF6 ubiquitination by interrupting the formation of TAK1-TAB2 complex in TLR4 signaling.
Moon G; Kim J; Min Y; Wi SM; Shim JH; Chun E; Lee KY
Cell Signal; 2015 Dec; 27(12):2524-33. PubMed ID: 26432169
[TBL] [Abstract][Full Text] [Related]
3. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner.
Sorrentino A; Thakur N; Grimsby S; Marcusson A; von Bulow V; Schuster N; Zhang S; Heldin CH; Landström M
Nat Cell Biol; 2008 Oct; 10(10):1199-207. PubMed ID: 18758450
[TBL] [Abstract][Full Text] [Related]
4. C1q-tumour necrosis factor-related protein-3 exacerbates cardiac hypertrophy in mice.
Ma ZG; Yuan YP; Zhang X; Xu SC; Kong CY; Song P; Li N; Tang QZ
Cardiovasc Res; 2019 May; 115(6):1067-1077. PubMed ID: 30407523
[TBL] [Abstract][Full Text] [Related]
5. Roles of the TRAF6 and Pellino E3 ligases in MyD88 and RANKL signaling.
Strickson S; Emmerich CH; Goh ETH; Zhang J; Kelsall IR; Macartney T; Hastie CJ; Knebel A; Peggie M; Marchesi F; Arthur JSC; Cohen P
Proc Natl Acad Sci U S A; 2017 Apr; 114(17):E3481-E3489. PubMed ID: 28404732
[TBL] [Abstract][Full Text] [Related]
6. Cereblon negatively regulates TLR4 signaling through the attenuation of ubiquitination of TRAF6.
Min Y; Wi SM; Kang JA; Yang T; Park CS; Park SG; Chung S; Shim JH; Chun E; Lee KY
Cell Death Dis; 2016 Jul; 7(7):e2313. PubMed ID: 27468689
[TBL] [Abstract][Full Text] [Related]
7. Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway.
Liao HH; Zhang N; Meng YY; Feng H; Yang JJ; Li WJ; Chen S; Wu HM; Deng W; Tang QZ
Oxid Med Cell Longev; 2019; 2019():6304058. PubMed ID: 31885808
[TBL] [Abstract][Full Text] [Related]
8. Smad6 inhibits non-canonical TGF-β1 signalling by recruiting the deubiquitinase A20 to TRAF6.
Jung SM; Lee JH; Park J; Oh YS; Lee SK; Park JS; Lee YS; Kim JH; Lee JY; Bae YS; Koo SH; Kim SJ; Park SH
Nat Commun; 2013; 4():2562. PubMed ID: 24096742
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 and TRAF6-dependent activation of TAK1 in the absence of TAB2 and TAB3.
Zhang J; Macartney T; Peggie M; Cohen P
Biochem J; 2017 Jun; 474(13):2235-2248. PubMed ID: 28507161
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin-3-gallate(EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity.
Zhang J; Lei Z; Huang Z; Zhang X; Zhou Y; Luo Z; Zeng W; Su J; Peng C; Chen X
Oncotarget; 2016 Nov; 7(48):79557-79571. PubMed ID: 27791197
[TBL] [Abstract][Full Text] [Related]
11. Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing Transforming Growth Factor β-Activated Kinase 1-Dependent Signaling Pathways.
Chen L; Huang J; Ji YX; Mei F; Wang PX; Deng KQ; Jiang X; Ma G; Li H
Hypertension; 2017 Feb; 69(2):249-258. PubMed ID: 27956576
[TBL] [Abstract][Full Text] [Related]
12. FBXW5 acts as a negative regulator of pathological cardiac hypertrophy by decreasing the TAK1 signaling to pro-hypertrophic members of the MAPK signaling pathway.
Hui X; Hu F; Liu J; Li C; Yang Y; Shu S; Liu P; Wang F; Li S
J Mol Cell Cardiol; 2021 Feb; 151():31-43. PubMed ID: 32971071
[TBL] [Abstract][Full Text] [Related]
13. TAB2, TRAF6 and TAK1 are involved in NF-kappaB activation induced by the TNF-receptor, Edar and its adaptator Edaradd.
Morlon A; Munnich A; Smahi A
Hum Mol Genet; 2005 Dec; 14(23):3751-7. PubMed ID: 16251197
[TBL] [Abstract][Full Text] [Related]
14. Chemical inhibition of TRAF6-TAK1 axis as therapeutic strategy of endotoxin-induced liver disease.
Kim SH; Baek SI; Jung J; Lee ES; Na Y; Hwang BY; Roh YS; Hong JT; Han SB; Kim Y
Biomed Pharmacother; 2022 Nov; 155():113688. PubMed ID: 36150308
[TBL] [Abstract][Full Text] [Related]
15. Poxviral protein A52 stimulates p38 mitogen-activated protein kinase (MAPK) activation by causing tumor necrosis factor receptor-associated factor 6 (TRAF6) self-association leading to transforming growth factor β-activated kinase 1 (TAK1) recruitment.
Stack J; Hurst TP; Flannery SM; Brennan K; Rupp S; Oda SI; Khan AR; Bowie AG
J Biol Chem; 2013 Nov; 288(47):33642-33653. PubMed ID: 24114841
[TBL] [Abstract][Full Text] [Related]
16. TAK1-binding protein 2 facilitates ubiquitination of TRAF6 and assembly of TRAF6 with IKK in the IL-1 signaling pathway.
Kishida S; Sanjo H; Akira S; Matsumoto K; Ninomiya-Tsuji J
Genes Cells; 2005 May; 10(5):447-54. PubMed ID: 15836773
[TBL] [Abstract][Full Text] [Related]
17. Oligomerization-primed coiled-coil domain interaction with Ubc13 confers processivity to TRAF6 ubiquitin ligase activity.
Hu L; Xu J; Xie X; Zhou Y; Tao P; Li H; Han X; Wang C; Liu J; Xu P; Neculai D; Xia Z
Nat Commun; 2017 Oct; 8(1):814. PubMed ID: 28993672
[TBL] [Abstract][Full Text] [Related]
18. The tyrosine kinase Syk differentially regulates Toll-like receptor signaling downstream of the adaptor molecules TRAF6 and TRAF3.
Lin YC; Huang DY; Chu CL; Lin YL; Lin WW
Sci Signal; 2013 Aug; 6(289):ra71. PubMed ID: 23962979
[TBL] [Abstract][Full Text] [Related]
19. RNF207 exacerbates pathological cardiac hypertrophy via post-translational modification of TAB1.
Yuan L; Bu S; Du M; Wang Y; Ju C; Huang D; Xu W; Tan X; Liang M; Deng S; Yang L; Huang K
Cardiovasc Res; 2023 Mar; 119(1):183-194. PubMed ID: 35352799
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin-specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1-dependent pathway.
Miao R; Lu Y; He X; Liu X; Chen Z; Wang J
J Cell Mol Med; 2020 Sep; 24(18):10946-10957. PubMed ID: 32798288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
